Alexion Buys A Complementary Business With Achillion
Executive Summary
The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.
You may also be interested in...
Apellis’ Empaveli Data In Frontline PNH Incremental, But Still Helpful
While the drug appears more efficacious than Alexion’s C5 inhibitors, those drugs could prove difficult to dethrone given how entrenched they are in PNH therapy.
AZ's Alexion Acquisition Looks Astute Bit Of Business
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
Alexion Buys Out Portola, But Analysts Don’t See Value
The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.